ACOBIOM is a biotechnology company specialized in the discovery of genomic or transcriptomic biomarkers and the development of innovative diagnostics. Thanks to its unique scientific expertise in the analysis of gene expression in blood cells and whole blood, ACOBIOM is positioned in the field of Precision Medicine and in the development of diagnostics to help in the choice of the most effective or the most adapted treatment to the biological (phenotypic) profile of patients.

Contact

busdev@acobiom.com

Address

1682 Rue de la Valsière – Cap Delta – Biopole Euromedecine II – 34790 GRABELS – FRANCE

Website

acobiom.com

Targeted indications : Breast cancer, Lung cancer, Gastrointestinal cancers

L’article ACOBIOM est apparu en premier sur OncoSTART.

Antineo is specialized in preclinical services to test future anticancer agents. We realize proof-of-concept studies in vitro, ex vitro and in vivo (CDX on immunocompromised, humanized mice, or syngeneic). Our expertise allows to optimize the preclinical steps of drug development strategies with the choice of the indication, relevant model, and adequate references/combinations. We also provide a panel of secondary resistance models (chemo and immunotherapies, immune checkpoint inhibitors).

Contact

contact@antineo.fr

Address

8 avenue Rockefeller 69008 Lyon

Website

www.antineo.fr

Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article Antineo SAS est apparu en premier sur OncoSTART.

Cureety, has developed and launched a digital telemonitoring platform for the follow-up of
patients with cancer and with chronic diseases, with three main goals:

1. Accompany the patients on their care pathway and improve their lives.
2. Assist caregivers and optimize their work.
3. Bring clinicians and pharma an innovative solution for collecting
high-quality real-world data on the diseases and their treatments.

Contact

francois@cureety.com

Address

33 rue de l’amirauté, 22100 Dinan

Website

https://www.cureety.com

Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article Cureety est apparu en premier sur OncoSTART.

Epigene Labs develops a data science platform for molecular and clinical data analysis in for drug discovery and translational research in oncology.

Contact

contact@epigenelabs.com

Address

7 square Gabriel Fauré 75017 Paris

Website

www.epigenelabs.com

Targeting innovation : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article Epigene Labs est apparu en premier sur OncoSTART.

Explicyte immuno-oncology offers preclinical contract research services for cancer immunotherapy drug discovery. Our preclinical CRO services range from (i) cell-based assays – for in vitro characterization of new anti-cancer immune modulators – (ii) in vivo proof-of-concept studies in validated syngeneic mouse tumor models (ii) to biomarker analysis through cutting-edge technologies such as digital histology, multispectral imaging as well as digital spatial profiling.

Contact

contact@explicyte.com

Address

229 Cours de l’Argonne, 33000 Bordeaux

Website

www.explicyte.com

Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article EXPLICYTE est apparu en premier sur OncoSTART.

HalioDx is an immuno-oncology diagnostic company providing first-in-class diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology. Immunoscore® assay family, is available internationally as a regulatory compliant tests to guide day to day oncologists’ decisions and help Biopharma in their clinical developments. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression.

Address

Luminy Biotech Entreprises 163 Avenue de Luminy 13288 Marseille Cedex 9

Website

www.haliodx.com

Targeted indications : Cancer du poumon, Cancer colorectal

L’article HalioDx est apparu en premier sur OncoSTART.

Drug repurposing in oncology / Harmonic Rediscovery platform / immunotherapy / predictive toxicology

Contact

souchet@harmonicpharma.com

Address

Campus Artem, 92 rue du Sergent Blandan, 54000 Nancy, France

Website

www.harmonicpharma.com

Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article Harmonic Pharma est apparu en premier sur OncoSTART.

The company ID-Solutions, created in 2016 and based near Montpellier, develops and produces a complete solution for the diagnosis of COVID-19 (RT-PCR test) as well as innovative and standardized tools for the diagnosis by digital PCR in oncology. on circulating DNA and tumor DNA.

Contact

info@id-solutions.fr

Address

310, rue Louis Pasteur 34790 GRABELS

Website

www.id-solutions.fr

Targeted innovation : Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Brain cancer, Skin cancer, Lymphoma, Myeloma

L’article ID SOLUTIONS est apparu en premier sur OncoSTART.

Keen Eye is developing an image analysis platform as well as AI algorithms for preclinical and clinical research. Keen Eye enables physicians and biologists to replicate and extend their visual expertise, identifying signals with high predictive value that are difficult to detect. They save precious time in decision-making, whether it is to diagnose, screen for a disease or assess the effectiveness of a drug, in a more precise and standardized way.

Contact

contact@keeneye.ai

Address

74 Rue du Faubourg Saint-Antoine, 75012 Paris

Website

www.keeneye.ai

Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article Keen Eye est apparu en premier sur OncoSTART.

Development of label free microscope and endoscope for instantaneous cancer tissues identification and virtual histology.

Contact

info@lightcore.tech

Address

37 rues d’Antibes, 06400, Cannes

Website

https://lightcore.tech/

Targeted indications : Colorectal cancer, Prostate cancer, Stomach cancer, Brain cancer, Gastrointestinal cancers

L’article Lightcore Technologies est apparu en premier sur OncoSTART.